SIGA Technologies Inc. (SIGA)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 6.4 |
Market Cap | 456.63M |
Revenue (ttm) | 173.82M |
Net Income (ttm) | 85.75M |
EPS (ttm) | 1.2 |
PE Ratio (ttm) | 5.33 |
Forward PE | 5.65 |
Analyst | n/a |
Ask | 6.41 |
Volume | 232,556 |
Avg. Volume (20D) | 492,496 |
Open | 6.35 |
Previous Close | 6.32 |
Day's Range | 6.29 - 6.42 |
52-Week Range | 4.26 - 12.83 |
Beta | 0.89 |
About SIGA
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothre...
Why Price Moved
News
2 months ago · seekingalpha.com
SIGA Technologies: Expansion Into mAbs Is Smart, But Eggs Remain In One BasketSIGA Technologies' stock has declined 37% since my "speculative buy" recommendation in August, driven by a muted response to the mpox outbreak. The initial recommendation was based on the WHO's mpox e...